Telangana government proposes to set up India’s first Biopharma-Hub to provide support to the biopharma research and development activities, featuring a scaleup manufacturing facility and a turnkey incubator/ lab space module.
The proposed facility, spread across 40,000 square feet, would come up at Hyderabad’s Genome Valley, which currently houses over 200 biopharma firms including few top global vaccine makers, at an outlay of Rs 60 crore in public private partnership.
In a statement, the Telangana government said companies that are in early stage clinical development but lack the requisite expertise and resources to navigate the complexities associated with business planning, cell line development, process development, technology, and/or regulatory and risk assessment, can leverage B-Hub facility to help breakdown roadblocks and improve likelihood of commercial success.
Industries minister KT Rama Rao said, “With Indian companies aggressively embarking on the global biosimilars opportunity, a biopharma scale-up facility will help them leapfrog in their endeavour, while reducing the time to market.”
He said inadequacy of scale-up infrastructure and funding was pushing cream of biopharma ventures to re-domicile themselves in different parts of the world. “Genome Valley is a very unique cluster and the kind of cutting edge scientific efforts happening in Genome Valley is just unmatchable by any other cluster in India and perhaps Asia,” he said.